Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.

AIMS To develop a risk-score model, based on available clinical data to assess absolute risk of type 2 diabetes among people with impaired glucose tolerance (IGT). METHODS Data from the study to prevent non-insulin dependent diabetes mellitus (STOP-NIDDM) investigating acarbose treatment in individuals with IGT were used to develop multivariable Cox proportional hazards model for the time to onset of diabetes. The final model equation was externally validated using data from the Finnish Cardiovascular Risk Factor (FINRISK) population. RESULTS The risk-score model included the variables acarbose treatment, gender, serum triglyceride level, waist circumference, fasting plasma glucose, height, history of cardiovascular disease (CVD) and hypertension. The final model yielded an area under the receiver-operating-characteristic curve (AUC(ROC)) of 0.64 when applied to people with IGT in the STOP-NIDDM, and 0.84 and 0.90 when applied to FINRISK population with IGT alone and IGT and normal glucose tolerance combined, respectively; AUC(ROC) is a measure of the discriminatory power of the model (1, perfect discrimination). CONCLUSIONS The STOP-NIDDM risk-score is a simple and validated tool that can identify high-risk individuals with IGT who would benefit most from type 2 diabetes or CVD prevention strategies, such as lifestyle management or early acarbose treatment.

[1]  Stefan R Bornstein,et al.  An Accurate Risk Score Based on Anthropometric, Dietary, and Lifestyle Factors to Predict the Development of Type 2 Diabetes , 2007, Diabetes Care.

[2]  Ralph B D'Agostino,et al.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions. , 2005, Statistics in medicine.

[3]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[4]  Heejung Bang,et al.  Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. , 2005, Diabetes care.

[5]  Mark Woodward,et al.  A Risk Score for Predicting Incident Diabetes in the Thai Population A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.

[6]  T. Valle,et al.  Prevalence of diabetes and impaired glucose regulation in 45‐ to 64‐year‐old individuals in three areas of Finland , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[7]  J. Tuomilehto,et al.  The major diabetes prevention trials , 2003, Current diabetes reports.

[8]  N. Wareham,et al.  Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice , 2000, Diabetes/metabolism research and reviews.

[9]  J Tuomilehto,et al.  Diabetes risk score in Oman: a tool to identify prevalent type 2 diabetes among Arabs of the Middle East. , 2007, Diabetes research and clinical practice.

[10]  N. Pronk,et al.  Identifying individuals at risk for the development of type 2 diabetes mellitus. , 2003, The American journal of managed care.

[11]  T. Valle,et al.  Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[12]  Tamara Harris,et al.  Predicting the development of diabetes in older adults: the derivation and validation of a prediction rule. , 2005, Diabetes care.

[13]  Jean Tichet,et al.  Predicting Diabetes: Clinical, Biological, and Genetic Approaches , 2008, Diabetes Care.

[14]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[15]  M. Engelgau,et al.  Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions. , 2004, Diabetes technology & therapeutics.

[16]  J. Tuomilehto,et al.  The European Perspective on Diabetes Prevention: development and Implementation of A European Guideline and training standards for diabetes prevention (IMAGE) , 2007, Diabetes & vascular disease research.

[17]  M. Laakso,et al.  The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. , 1998, Diabetes care.

[18]  L. Bouter,et al.  Performance of an NIDDM Screening Questionnaire Based on Symptoms and Risk Factors , 1997, Diabetes Care.

[19]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[20]  Jaakko Tuomilehto,et al.  Determinants for the Effectiveness of Lifestyle Intervention in the Finnish Diabetes Prevention Study , 2008, Diabetes Care.

[21]  S. Haffner,et al.  Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? , 2002, Annals of Internal Medicine.

[22]  J. Tuomilehto,et al.  The European perspective of type 2 diabetes prevention: diabetes in Europe--prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. , 2008, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[23]  J M Dekker,et al.  Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. , 2001, JAMA.

[24]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[25]  P. Zimmet,et al.  Diagnosis and classification of diabetes mellitus , 2002 .

[26]  M. Harris,et al.  Undiagnosed NIDDM: Clinical and Public Health Issues , 1993, Diabetes Care.

[27]  GerdAssmann,et al.  Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002 .

[28]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[29]  R. Jackson,et al.  Updated New Zealand cardiovascular disease risk-benefit prediction guide , 2000, BMJ : British Medical Journal.

[30]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[31]  M. Engelgau,et al.  A New and Simple Questionnaire to Identify People at Increased Risk for Undiagnosed Diabetes , 1995, Diabetes Care.

[32]  Richard Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[33]  M. Laakso,et al.  The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data , 1998, Diabetes Care.

[34]  Jaakko Tuomilehto,et al.  The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.

[35]  Bendix Carstensen,et al.  A Danish diabetes risk score for targeted screening: the Inter99 study. , 2004, Diabetes care.

[36]  Aziz Sheikh,et al.  Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore , 2009, BMJ : British Medical Journal.

[37]  J. Lindström,et al.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study , 2006, The Lancet.

[38]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[39]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[40]  Hilkka Soininen,et al.  Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study , 2006, The Lancet Neurology.

[41]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[42]  P. Zimmet The burden of type 2 diabetes: are we doing enough? , 2003, Diabetes & Metabolism.

[43]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[44]  V. Mohan,et al.  A simplified Indian Diabetes Risk Score for screening for undiagnosed diabetic subjects. , 2005, The Journal of the Association of Physicians of India.

[45]  R. Holle,et al.  Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey 2000. , 2005, Archives of internal medicine.

[46]  J. Shaw,et al.  Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[47]  R. D'Agostino,et al.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions , 2004, Statistics in medicine.